A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
Radford, John A
AffiliationDepartment of Haematology, Leeds Teaching Hospitals NHS Trust Clinical Trials Research Unit, University of Leeds, Leeds Royal Liverpool University Hospital, Liverpool Hull York Medical School, University of York, York Leicester Royal Infirmary, Leicester University Hospital of Wales, Cardiff Birmingham Heartlands Hospital, Birmingham Christie NHS Foundation Trust and University of Manchester, Manchester St. Helier Hospital, Carshalton Royal Marsden Hospital, Sutton Darent Valley Hospital, Dartford East Kent Hospitals NHS Trust, Canterbury, UK.
MetadataShow full item record
AbstractCombination fludarabine (F), cyclophosphamide (C) and rituximab (R) is the standard front-line therapy in chronic lymphocytic leukaemia (CLL), but appropriate treatment of relapsed/refractory CLL is less clear. Combined FC and mitoxantrone (M) has been reported to be effective in a single arm study, and rituximab when added to chemotherapy in CLL is synergistic. A randomized, two-stage, Phase II trial of FCM and FCM-R was conducted in relapsed CLL. The primary endpoint was response rate 2 months after therapy, assessed according to the 2008 International Workshop CLL criteria. In addition, minimal residual disease (MRD) in the marrow was studied 2 months after therapy, with MRD negativity defined as <0·01% CLL cells. Fifty-two patients were entered, 26 in each arm. The overall response rates to FCM and FCM-R were 58% and 65% respectively. Combined complete response (CR) and CR with incomplete marrow recovery [CR(i)] was 15% (95% confidence interval [CI]:4-35%) for FCM and 42% (95%CI:23-63%) for FCM-R, with eight patients achieving MRD negativity (3 FCM; 5 FCM-R). The toxicity of both regimens was acceptable. In conclusion, the addition of rituximab to FCM improves the response rates in relapsed CLL, resulting in more complete remissions and without additional safety concerns. Efficacy and safety should be fully tested in a randomized Phase III trial.
CitationA randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. 2011:Br J Haematol
JournalBritish Journal of Haematology
- Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
- Authors: Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, González Diaz M, Abella E, Delgado J, Carbonell F, García Marco JA, Escoda L, Ferrer S, Monzó E, González Y, Estany C, Jarque I, Salamero O, Muntañola A, Montserrat E
- Issue date: 2009 Sep 20
- Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
- Authors: Robak T, Lech-Maranda E, Robak P
- Issue date: 2010 Oct
- Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
- Authors: Bosch F, Ferrer A, Villamor N, González M, Briones J, González-Barca E, Abella E, Gardella S, Escoda L, Pérez-Ceballos E, Asensi A, Sayas MJ, Font L, Altés A, Muntañola A, Bertazzoni P, Rozman M, Aymerich M, Giné E, Montserrat E
- Issue date: 2008 Jan 1
- Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
- Authors: Howard DR, Munir T, McParland L, Rawstron AC, Chalmers A, Gregory WM, O'Dwyer JL, Smith A, Longo R, Varghese A, Smith A, Hillmen P
- Issue date: 2017 May
- Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.
- Authors: Bosch F, Ferrer A, López-Guillermo A, Giné E, Bellosillo B, Villamor N, Colomer D, Cobo F, Perales M, Esteve J, Altés A, Besalduch J, Ribera JM, Montserrat E, GELCAB (Grup per l'Estudi dels Limfomes a Catalunya i Balears).
- Issue date: 2002 Dec